Results 11 to 20 of about 2,934,766 (329)
Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective [PDF]
Metabolites, 2021 Histone deacetylases (HDACs) are epigenetic enzymes that play a central role in gene regulation and are sensitive to the metabolic state of the cell.
Jacob King +2 more
semanticscholar +4 more sources
HDAC Inhibitors in Acute Myeloid Leukemia [PDF]
Cancers, 2019 Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled proliferation, differentiation arrest, and accumulation of immature myeloid progenitors.
Edurne San José-Enériz +3 more
semanticscholar +4 more sources
HDACs and HDAC Inhibitors in Cancer Development and Therapy. [PDF]
Cold Spring Harbor Perspectives in Medicine, 2016 Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.
Yixuan Li, E. Seto
semanticscholar +3 more sources
Cancers, 2021 Simple Summary Beyond mutations, epigenetic changes have been described as drivers for cancer as well. While leaving the overall DNA structure intact, they can be responsible for tumor malignancy by mediating the transcriptional upregulation of oncogenes.
R. Jenke +4 more
semanticscholar +1 more source
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Molecules, 2022 Histone deacetylases (HDACs) are a large family of epigenetic metalloenzymes that are involved in gene transcription and regulation, cell proliferation, differentiation, migration, and death, as well as angiogenesis.
Mateusz Daśko +3 more
semanticscholar +1 more source
HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Cancers, 2021 Simple Summary Tumor heterogeneity promotes the development of drug resistance in cancer. HDAC inhibitors modulate several processes that contribute to intra-tumoral heterogeneity. With careful consideration of the underlying biology, HDAC inhibitors can
Dimitris Karagiannis, T. Rampias
semanticscholar +1 more source
HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
Translational Oncology, 2022 Histone deacetylases (HDACs) are enzymes that play a key role in the epigenetic regulation of gene expression by remodeling chromatin. Inhibition of HDACs is a prospective therapeutic approach for reversing epigenetic alteration in several diseases.
Geetha Shanmugam +2 more
doaj +1 more source
HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
Cancer Drug Resistance, 2022 Epigenetic mechanisms play an important role in the development and persistence of cancer, and histone deacetylase (HDAC) inhibitors are promising anticancer drugs targeting epigenetic modes.
B. Biersack, B. Nitzsche, M. Höpfner
semanticscholar +1 more source
Pharmaceuticals, 2023 Histone deacetylases (HDAC) represent promising epigenetic targets for several diseases including different cancer types. The HDAC inhibitors approved to date are pan-HDAC inhibitors and most show a poor selectivity profile, side effects, and in ...
Emre F. Bülbül +7 more
doaj +1 more source
Nɛ-acetyl lysine derivatives with zinc binding groups as novel HDAC inhibitors [PDF]
Royal Society Open Science, 2019 HDAC inhibitors have been developed very rapidly in clinical trials and even in approvals for treating several cancers. However, there are few reported HDAC inhibitors designed from Nɛ-acetyl lysine.
Fang Wang +9 more
doaj +1 more source